Shishan Zhou, Changliang Zhang, Zhipeng Zhang, Yongbin Hu, Lina Zhao, Wentao Hu, Si Chen, Bin Li, Sheng Xiao
{"title":"一种新型 HMGA2::KITLG融合型脂肪肉瘤伴有MDM2和HMGA2扩增。","authors":"Shishan Zhou, Changliang Zhang, Zhipeng Zhang, Yongbin Hu, Lina Zhao, Wentao Hu, Si Chen, Bin Li, Sheng Xiao","doi":"10.1002/gcc.23200","DOIUrl":null,"url":null,"abstract":"<p>High-mobility group AT-hook 2 (<i>HMGA2</i>) is rearranged in various types of mesenchymal tumors, particularly lipomas. <i>HMGA2</i> is also co-amplified with mouse double minute 2 (<i>MDM2</i>) in well-differentiated liposarcoma/dedifferentiated liposarcoma (WDLPS/DDLPS). We report a case of relapsed DDLPS with a novel in-frame fusion between <i>HMGA2</i> and <i>KITLG</i>, which encodes the ligand for KIT kinase, a critical protein involved in gametogenesis, hematopoiesis, and melanogenesis. The <i>HMGA2</i> breakpoint is in intron 3, a commonly observed location for <i>HMGA2</i> rearrangements, while the <i>KITLG</i> breakpoint is in intron 2, leading to a fusion protein that contains almost the entire coding sequence of <i>KITLG</i>. By immunohistochemical staining, tumor cells expressed KIT and showed phosphorylated MAPK, a major KIT downstream target. We suggest an oncogenic mechanism that involves the overexpression of <i>KITLG</i> caused by its rearrangement with <i>HMGA2</i>, leading to the constitutive activation of KIT kinase. While <i>MDM2</i> amplification was observed in both the primary tumor and the relapsed tumor, the <i>HMGA2::KITLG</i> was only present in the relapsed tumor, indicating the role of <i>HMGA2::KITLG</i> in disease progression.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel HMGA2::KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2\",\"authors\":\"Shishan Zhou, Changliang Zhang, Zhipeng Zhang, Yongbin Hu, Lina Zhao, Wentao Hu, Si Chen, Bin Li, Sheng Xiao\",\"doi\":\"10.1002/gcc.23200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>High-mobility group AT-hook 2 (<i>HMGA2</i>) is rearranged in various types of mesenchymal tumors, particularly lipomas. <i>HMGA2</i> is also co-amplified with mouse double minute 2 (<i>MDM2</i>) in well-differentiated liposarcoma/dedifferentiated liposarcoma (WDLPS/DDLPS). We report a case of relapsed DDLPS with a novel in-frame fusion between <i>HMGA2</i> and <i>KITLG</i>, which encodes the ligand for KIT kinase, a critical protein involved in gametogenesis, hematopoiesis, and melanogenesis. The <i>HMGA2</i> breakpoint is in intron 3, a commonly observed location for <i>HMGA2</i> rearrangements, while the <i>KITLG</i> breakpoint is in intron 2, leading to a fusion protein that contains almost the entire coding sequence of <i>KITLG</i>. By immunohistochemical staining, tumor cells expressed KIT and showed phosphorylated MAPK, a major KIT downstream target. We suggest an oncogenic mechanism that involves the overexpression of <i>KITLG</i> caused by its rearrangement with <i>HMGA2</i>, leading to the constitutive activation of KIT kinase. While <i>MDM2</i> amplification was observed in both the primary tumor and the relapsed tumor, the <i>HMGA2::KITLG</i> was only present in the relapsed tumor, indicating the role of <i>HMGA2::KITLG</i> in disease progression.</p>\",\"PeriodicalId\":12700,\"journal\":{\"name\":\"Genes, Chromosomes & Cancer\",\"volume\":\"63 1\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2023-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genes, Chromosomes & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/gcc.23200\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.23200","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
A novel HMGA2::KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2
High-mobility group AT-hook 2 (HMGA2) is rearranged in various types of mesenchymal tumors, particularly lipomas. HMGA2 is also co-amplified with mouse double minute 2 (MDM2) in well-differentiated liposarcoma/dedifferentiated liposarcoma (WDLPS/DDLPS). We report a case of relapsed DDLPS with a novel in-frame fusion between HMGA2 and KITLG, which encodes the ligand for KIT kinase, a critical protein involved in gametogenesis, hematopoiesis, and melanogenesis. The HMGA2 breakpoint is in intron 3, a commonly observed location for HMGA2 rearrangements, while the KITLG breakpoint is in intron 2, leading to a fusion protein that contains almost the entire coding sequence of KITLG. By immunohistochemical staining, tumor cells expressed KIT and showed phosphorylated MAPK, a major KIT downstream target. We suggest an oncogenic mechanism that involves the overexpression of KITLG caused by its rearrangement with HMGA2, leading to the constitutive activation of KIT kinase. While MDM2 amplification was observed in both the primary tumor and the relapsed tumor, the HMGA2::KITLG was only present in the relapsed tumor, indicating the role of HMGA2::KITLG in disease progression.
期刊介绍:
Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.